MedTrace Logo

Liquid Biopsy in High-grade Gliomas and Meningiomas

NCT05630664 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2022-12-02

No results posted yet for this study

Summary

The general objective of this project is to evaluate the value of cell-free DNA circulating in plasma as a marker of tumor evolution in patients with high-grade gliomas and meningiomas.

To this end, we propose to longitudinally collect four samples of plasma at the following time points:

* T0: before surgery;
* T1: one month after surgery;
* T2: one month after the end of radiotherapy;
* T3 at the time of radiological progression.

The goal is to evaluate whether changes in plasma concentration of circulating cell-free DNA can help predict progression-free survival, overall survival, and response to therapies.

Conditions

Sponsors & Collaborators

  • Alleanza Contro il Cancro

    collaborator OTHER

  • IRCCS San Raffaele

    lead OTHER

Principal Investigators

  • Gaetano Finocchiaro, MD · Ospedale San Raffaele, Milano, Italy

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2025-09-30
Completion
2025-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05630664 on ClinicalTrials.gov